Silverarc Capital Management »

Clene shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Clene (CLNN) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Clene

Tip: Access up to 7 years of quarterly data

All positions including Clene held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Clene by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $248k 500k 0.50
2023-06-30 $220k 250k 0.88
2022-09-30 $4.9M 1.7M 2.80

More positions owned by Silverarc Capital Management

ImmunoGen Long Option Calls Call Option
SPRD S&P Biotech ETF Long Option Calls Call Option (XBI)
Akero Therapeutics Long Option Calls Call Option (AKRO)
Mirati Therapeutics Long Option Calls Call Option
Morphic Holding Equities (MORF)
Merus NV Equities (MRUS)
CymaBay Therapeutics Long Option Calls Call Option
Soleno Therapeutics Equities (SLNO)
Intra-Cellular Therapies Equities (ITCI)
Poseida Therapeutics Equities (PSTX)
Krystal Biotech Equities (KRYS)
Mersana Therapeutics Long Option Calls Call Option (MRSN)
KalVista Pharmaceuticals Long Option Calls Call Option (KALV)
Biogen Idec Equities (BIIB)
Urogen Pharma Equities (URGN)

View all positions for Silverarc Capital Management

Top funds holding Clene

AWM Investment Company
Vanguard Group
Alyeska Investment Group
Scoggin
Lunt Capital Management
Citadel Advisors
BlackRock
AE Wealth Management
Group One Trading
Susquehanna International
Csenge Advisory Group
Condor Capital Management
SRS Capital Advisors
Millennium Management
CI Private Wealth

View all funds holding Clene